NHS England to prioritise 'tumour agnostic' cancer drugs

NHS England is to prioritise cancer drugs that target tumours according to their genetic makeup rather than where they originate in the body, the organisation’s chief executive has said.

Gilead joins protein degradation drive with Nurix deal

Daiichi waits on FDA as AML drug quizartinib approved in Jap...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.

AZ sees triple approval in Japan for cancer and COPD drugs

AstraZeneca has seen three of its drugs approved by the Japanese regulator – a new indication for its cancer drug Lynparza, and two new combination therapies for patients with chronic obstr

Japan approves Roche's tumour agnostic cancer drug Rozlytrek

Japan has become the first country to approve Roche’s personalised cancer drug Rozlytrek (entrectinib).

Exclusive Interview with Dr Zisis Kozlakidis ahead of Bioban...

Dr Zisis Kozlakidis Head of Laboratories and Biobanking